Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

2018 ◽  
Vol 28 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Jeong-Yeol Park ◽  
Dae-Yeon Kim ◽  
Dae-Shik Suh ◽  
Jong-Hyeok Kim ◽  
Yong-Man Kim ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Stage I ◽  
Ovarian Clear Cell Carcinoma ◽  
Ovarian Endometriosis ◽  
Early Stage Disease ◽  
Group 2 ◽  
Group 1

IntroductionThe aim of this study was to evaluate the significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma (OCCC).MethodsPatients with OCCC were divided into 2 groups according to the presence of ovarian endometriosis: group 1, no coexisting ovarian endometriosis; group 2, clear cell carcinoma arising from ovarian endometriosis or the presence of ovarian endometriosis elsewhere in the ovary. Clinicopathologic characteristics, disease-free survival (DFS), and overall survival (OS) were compared between the 2 groups.ResultsOf 155 patients with OCCC, 77 were categorized into group 1 and 78 into group 2. Group 2 patients were younger than group 1 (median age, 48 vs 51 years; P = 0.005) and had higher incidence of early-stage disease (stage I, 77% vs 58%; P = 0.001) and lower incidence of lymph node metastasis (4% vs 17%; P = 0.008). Group 2 patients were observed to have a significantly higher 5-year DFS (P < 0.001) and OS (P = 0.001) compared with group 1. In stage I disease, group 2 had a significantly higher 5-year DFS (P = 0.004) and OS (P = 0.016) than did group 1. In the multivariate analysis, coexisting endometriosis and advanced International Federation of Obstetrics and Gynecology stage were significant factors for both DFS and OS rates.ConclusionsOvarian clear cell carcinoma with endometriosis was found more frequently in younger women and had a higher incidence of early-stage disease and a lower incidence of lymph node metastasis compared with OCCC without endometriosis. Ovarian endometriosis was associated with improved prognostic factors and a better DFS and OS even in stage I disease. Ovarian endometriosis was an independent prognostic factor for OCCC.

scholarly journals The Frequency and Clinical Implication of Mismatch Repair Protein Deficiency in Chinese Patients with Ovarian Clear Cell Carcinoma

2021 ◽  
Author(s):  
Shuang Ye ◽  
Shuling Zhou ◽  
Siyuan Zhong ◽  
Boer Shan ◽  
Wenhua Jiang ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Mismatch Repair ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Progression Free Survival ◽  
Chinese Patients ◽  
Ovarian Clear Cell Carcinoma ◽  
Early Stage Disease ◽  
Platinum Sensitive

Abstract Background: To assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features.Methods: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 were performed on whole section slides. Results were correlated with clinicopathologic variables.Results: A total of 108 cases were included in the study, with a median age of 52 years at first diagnosis. Early-stage disease and platinum-sensitive recurrence accounted for 62.3% and 69.6%, respectively. Overall, the estimated 5-year overall survival was 70.3% and 20.7% in patients with early and late stage tumor, respectively. Deficient MMR were identified in 5.6% (6/108) of the cohort and included MSH2/MSH6 (n=4) and MLH1/PMS2 (n=2). The average age of the six patients was 45.6 years. The rate of MMR-deficient tumors in women ≤ 50 years was relatively higher than that those over 50 years (10.0% Vs. 2.9%; P=0.266). A half of the patients with deficient MMR were diagnosed with a synchronous (endometrial or colorectal) and metachronous (endometrial) cancer, significantly more than those intact counterparts (P=0.002). All the six patients had early-stage tumor and the majority (83.3%) were platinum-sensitive. The median progression-free survival was slightly higher in patients with defective MMR expression than those intact counterparts (30 months Vs. 27 months), although significance was not achieved (P=0.471). Conclusions: Ovarian CCC patients with young age and concurrent diagnosis of endometrial and colorectal cancer are more likely to have MMR-deficient tumors. It merits further evaluation whether patients harboring MMR abnormality has favorable prognosis.

Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes?

2016 ◽  
Vol 27 (1) ◽  
pp. 69-76 ◽  
Author(s):  
Julie M.V. Nguyen ◽  
Geneviève Bouchard-Fortier ◽  
Marcus Q. Bernardini ◽  
Eshetu G. Atenafu ◽  
Guangming Han ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Stage I ◽  
High Rate ◽  
Advanced Stage ◽  
Early Stage Disease ◽  
Uterine Clear Cell Carcinoma

ObjectivesWomen with uterine clear cell carcinoma (UCCC) are at high risk of relapse. Adjuvant chemotherapy (CT) is often recommended, although its effectiveness remains controversial. Our objective was to evaluate treatment-related outcomes of patients with UCCC, particularly those treated with adjuvant CT.MethodsIn this retrospective cohort study, patients diagnosed with UCCC at 2 academic cancer centers from 2000 to 2014 were included. Clinical, surgical, and pathological data were collected. Survival estimates were obtained using the Kaplan-Meier method and compared by log rank test. Multivariable analysis was used to determine the effect of CT and radiation therapy (RT) on overall survival (OS) and progression-free survival (PFS).ResultsWe included 146 patients with UCCC, with a median follow-up of 27 months (range, 1–160). Ninety-five (65%) patients presented with stage I to II disease and 51 (35%) with stage III to IV disease. Forty-six percent of patients with clinical stage I were upstaged after surgery: 29% were upstaged to stages III and IV. Thirty-one percent of patients with early-stage disease and 70% with advanced-stage received CT. Among recurrences, the majority had distant relapse in both early-stage (61.5%) and advanced-stage (96.3%) diseases. In both patients with early-stage and advanced-stage diseases, adjuvant CT did not improve OS or PFS. On multivariate analysis, CT was not a significant factor associated with improved PFS (hazard ratio [HR], 1.37; 95% confidence interval [CI], 0.69–2.71;P= 0.37) or OS (HR, 0.58; 95% CI, 0.24–1.38;P= 0.22), whereas RT was associated with improved PFS (HR, 0.51; 95% CI, 0.29–0.90;P= 0.02) and OS (HR, 0.19; 95% CI, 0.09–0.42;P< 0.001).ConclusionsThe high rate of upstaging after surgery highlights the importance of lymph node assessment. The high rate of distant recurrence questions the effectiveness of current CT regimens and warrants the development of novel systemic approaches. The role of adjuvant RT deserves further study.

scholarly journals The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Nobuhisa Yoshikawa ◽  
Kosuke Yoshida ◽  
Satoshi Tamauchi ◽  
Yoshiki Ikeda ◽  
Kimihiro Nishino ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Prognostic Nutritional Index ◽  
Ovarian Clear Cell Carcinoma ◽  
Nutritional Index

scholarly journals Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma

2018 ◽  
Vol 29 (2) ◽  
Author(s):  
Hiroyuki Yamazaki ◽  
Yukiharu Todo ◽  
Chisa Shimada ◽  
Sho Takeshita ◽  
Shinichiro Minobe ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Ovarian Clear Cell Carcinoma

A North American population-based outcome for early-stage ovarian clear cell carcinoma (OCCC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 5062-5062
Author(s):  
P. Hoskins ◽  
J. S. Albarrak ◽  
N. Le ◽  
A. Tinker ◽  
K. Swenerton ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
North American ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Population Based ◽  
North American Population ◽  
American Population ◽  
Ovarian Clear Cell Carcinoma

Recurrence factors of stage I ovarian clear cell carcinoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16577-e16577
Author(s):  
Yuji Takei ◽  
Hiroyuki Fujiwara ◽  
Shizuo Machida ◽  
Akiyo Taneichi ◽  
Suzuyo Takahashi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Ovarian Clear Cell Carcinoma

Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma: Is it Necessary for Stage IA?

2012 ◽  
Vol 22 (7) ◽  
pp. 1143-1149 ◽  
Author(s):  
Mika Mizuno ◽  
Hiroaki Kajiyama ◽  
Kiyosumi Shibata ◽  
Kimio Mizuno ◽  
Osamu Yamamuro ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Surgical Staging ◽  
Recurrence Free Survival ◽  
Ovarian Clear Cell Carcinoma ◽  
Free Survival ◽  
Stage Ia

BackgroundIt is controversial whether patients with stage I ovarian clear cell carcinoma (CCC) benefit from postoperative chemotherapy. This study was designed to evaluate the postoperative outcomes associated with the inclusion or exclusion of adjuvant therapy in these patients.MethodsA total of 185 patients who were treated for stage I CCC between 1991 and 2007 were retrospectively evaluated. All of the patients had received comprehensive surgical staging, and their condition had been diagnosed by a central pathological review system. Only one patient with stage IB was excluded from this study.ResultsMedian follow-up time was 62 months (range 7–191 months). Median age was 52 years (30–75 years). There were 41, 93, and 50 patients in stage IA, intraoperative capsule ruptured IC (rupture-IC), and all other-IC groups, respectively. The 5-year recurrence-free survival rates for the substage were 97.6%, 87.8%, and 70.4% (P < 0.001), respectively. Among 134 patients consisting of those in the stage IA and rupture-IC groups, 91 patients received adjuvant chemotherapy (AC) and 43 patients did not (non-AC). There was no significant survival difference in each substage group between the non-AC and AC groups in 5-year recurrence-free survival rate (stage IA, 100% vs 93.8%; rupture-IC, 94.1% vs 86.6%). Multivariate analysis demonstrated that there was no significant prognostic factor for both recurrence and survival among the IA and rupture-IC groups. Postoperative therapy, regimen, and chemotherapy cycles were not significantly affected.ConclusionsThis study indicates that adjuvant chemotherapy does not contribute to the improving prognosis of stage IA ovarian CCC. Whereas the histological type is CCC, the routine adjuvant chemotherapy after comprehensive surgical staging may be unnecessary for patients with at least stage IA.

scholarly journals Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma

2019 ◽  
Vol 30 (6) ◽  
Author(s):  
Kosuke Yoshida ◽  
Nobuhisa Yoshikawa ◽  
Akira Shirakawa ◽  
Kaoru Niimi ◽  
Shiro Suzuki ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Prognostic Value ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Neutrophil To Lymphocyte Ratio ◽  
Ovarian Clear Cell Carcinoma ◽  
Lymphocyte Ratio
Sign in / Sign up

Export Citation Format

Share Document